- Home
- TMQ vs EXEL Comparison
TMQ vs EXEL Comparison
Compare TMQ & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TMQ
- EXEL
- Stock Information
- Founded
- TMQ 2004
- EXEL 1994
- Country
- TMQ Canada
- EXEL United States
- Employees
- TMQ N/A
- EXEL N/A
- Industry
- TMQ Precious Metals
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TMQ Basic Materials
- EXEL Health Care
- Exchange
- TMQ Nasdaq
- EXEL Nasdaq
- Market Cap
- TMQ N/A
- EXEL 9.8B
- IPO Year
- TMQ N/A
- EXEL 2000
- Fundamental
- Price
- TMQ $1.60
- EXEL $36.17
- Analyst Decision
- TMQ
- EXEL Buy
- Analyst Count
- TMQ 0
- EXEL 18
- Target Price
- TMQ N/A
- EXEL $37.59
- AVG Volume (30 Days)
- TMQ 501.3K
- EXEL 2.2M
- Earning Date
- TMQ 04-02-2025
- EXEL 05-13-2025
- Dividend Yield
- TMQ N/A
- EXEL N/A
- EPS Growth
- TMQ N/A
- EXEL 170.77
- EPS
- TMQ N/A
- EXEL 1.76
- Revenue
- TMQ N/A
- EXEL $2,168,701,000.00
- Revenue This Year
- TMQ N/A
- EXEL $5.78
- Revenue Next Year
- TMQ N/A
- EXEL $10.94
- P/E Ratio
- TMQ N/A
- EXEL $20.64
- Revenue Growth
- TMQ N/A
- EXEL 18.50
- 52 Week Low
- TMQ $0.39
- EXEL $20.14
- 52 Week High
- TMQ $2.09
- EXEL $40.26
- Technical
- Relative Strength Index (RSI)
- TMQ 52.11
- EXEL 43.89
- Support Level
- TMQ $1.59
- EXEL $34.90
- Resistance Level
- TMQ $1.70
- EXEL $40.26
- Average True Range (ATR)
- TMQ 0.10
- EXEL 1.21
- MACD
- TMQ 0.00
- EXEL -0.19
- Stochastic Oscillator
- TMQ 72.00
- EXEL 23.69
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.